719 related articles for article (PubMed ID: 31615983)
1. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
4. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
5. ZEB1 Transcriptionally Activates PHGDH to Facilitate Carcinogenesis and Progression of HCC.
Wang H; Lin F; Xu Z; Yu S; Li G; Liao S; Zhao W; Zhang F; Wang J; Wang S; Ouyang C; Zhang C; Xia H; Wu Y; Jiang B; Li Q
Cell Mol Gastroenterol Hepatol; 2023; 16(4):541-556. PubMed ID: 37331567
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
7. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
8. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
[No Abstract] [Full Text] [Related]
9. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
10. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
11. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
12. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
15. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
16. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
[TBL] [Abstract][Full Text] [Related]
17. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
Li L; Yu S; Hu Q; Hai Y; Li Y
Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib: a promising treatment for hepatocellular carcinoma.
Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
[No Abstract] [Full Text] [Related]
19. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
